Výsledky vyhledávání - "Neda Alrawashdh"

Expanded access to anticancer treatments from conversion to biosimilar pegfilgrastim-cbqv in US breast cancer patients

Autor: Neda Alrawashdh, Ali McBride, Ivo Abraham, Karen MacDonald

Publikováno v: Future Oncology. 18:363-373

Lay abstract Pegfilgrastim is used to prevent low white blood cell count in patients receiving chemotherapy. Comparable to a generic version of a drug, a biosimilar is a follow-on version of a biologic treatment. We calculated the savings from using

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccf0795d869210eed6f0f9402b53768c
https://doi.org/10.2217/fon-2021-0979

Zobrazit plný text záznamu

Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral access to FOLFIRINOX treatment for metastatic pancreatic cancer

Autor: Ivo Abraham, Neda Alrawashdh, Karen MacDonald, Ali McBride

Publikováno v: Future Oncology. 17:4561-4570

Aim: To estimate the cost-savings from conversion to biosimilar pegfilgrastim-cbqv that can be reallocated to provide budget-neutral expanded access to FOLFIRINOX in patients with metastatic pancreatic cancer. Methods: Simulation modeling in a panel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1eebc48bd7cf0d3e9a24a12b5853f703
https://doi.org/10.2217/fon-2021-0718

Zobrazit plný text záznamu

Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985–2017)

Autor: Joann B. Sweasy, Ivo Abraham, Brian L. Erstad, Daniel O. Persky, Ali McBride, Neda Alrawashdh

Publikováno v: Annals of Hematology. 100:2501-2512

In this population-based study, we used the SEER database (1985–2015) to examine survival outcomes in chronic lymphocytic leukemia (CLL) patients followed up to the era of advanced treatments including targeted therapies. Data were extracted for pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::02843a17d96a83f4c75460e2102df816
https://doi.org/10.1007/s00277-021-04600-1

Zobrazit plný text záznamu

Racial/Ethnic, Sex, and Income Disparities in Overall Survival (OS) in Chronic Lymphocytic Leukemia (CLL) Patients in the Era of Targeted Therapy: Surveillance, Epidemiology, and End Results (SEER) Registry Analysis (2009-2019)

Autor: Neda Alrawashdh, Ivo Abraham

Publikováno v: Blood. 140:8063-8064

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::80b7e07706c14787de8ae4102aab960d
https://doi.org/10.1182/blood-2022-156940

Zobrazit plný text záznamu

Cost-Effectiveness Analyses of First Line Ibrutinib Versus Acalabrutinib Versus Zanubrutinib Followed By Second Line Venetoclax Plus Rituximab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients

Autor: Neda Alrawashdh, Ali McBride, Ivo Abraham

Publikováno v: Blood. 140:2155-2156

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a129f9d99168e700c5370261009bc9b3
https://doi.org/10.1182/blood-2022-156948

Zobrazit plný text záznamu

Retrospective evaluation of safety and effectiveness of same-day pegfilgrastim in patients with lung cancer

Autor: Neda Alrawashdh, Jamie Vraney, Briana M Choi, Abdulaali R Almutairi, Ivo Abraham, Ali McBride

Publikováno v: Future oncology (London, England). 18(19)

Chemotherapy is intended to kill fast-growing cancer cells but can also kill immune cells that are needed to prevent infections. When too many immune cells are killed by chemotherapy, patients with cancer may experience febrile neutropenia, a serious

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e49bbfbcd524632ebb919816963c1e0
https://pubmed.ncbi.nlm.nih.gov/35477322

Zobrazit plný text záznamu

Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv

Autor: Karen MacDonald, Neda Alrawashdh, Ali McBride, Ivo Abraham

Publikováno v: Journal of Medical Economics. 23:1466-1476

In this pharmacoeconomic simulation, we: (1) modeled the cost-efficiency of converting patients from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv for prophylaxis of chemotherapy-induced (febrile) neutropenia (CIN/FN) from the US payer per

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba173a2ad20fca976a7e555c16c81216
https://doi.org/10.1080/13696998.2020.1833339

Zobrazit plný text záznamu

Cost-effectiveness and value of information analyses of Bruton's tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States

Autor: Neda Alrawashdh, Ali McBride, Marion Slack, Daniel Persky, Leslie Andritsos, Ivo Abraham

Publikováno v: Journal of managed carespecialty pharmacy. 28(4)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7249dda0bb5596372caa97d94555209
https://pubmed.ncbi.nlm.nih.gov/35332792

Zobrazit plný text záznamu

Comparing jurisdiction-specific pharmaco-economic evaluations using medical purchasing power parities

Autor: Briana M. Choi, Rachel B. Abraham, Hala Halawah, Matthias Calamia, Mavis Obeng-Kusi, Neda Alrawashdh, Daniel Arku, Ivo Abraham

Publikováno v: Journal of medical economics. 24(sup1)

To demonstrate how medical purchasing power parities (mPPP) may harmonize economic evaluations from different jurisdictions and enable comparisons across jurisdictions.We describe the use of mPPPs and illustrate this with an example of economic evalu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c67de252acced1358e39772488dba89
https://pubmed.ncbi.nlm.nih.gov/34866529

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání